Supplier News: WuXi Biologics, Resilience, Carbogen Amics, Simtra & More
The latest from CDMOs, CMOs, and suppliers featuring WuXi Biologics, Euroapi, Simtra BioPharma Solutions, MilliporeSigma, Made Scientific, PharmaLogic, Fujifilm, Antheia, Carbogen Amcis, Cellares, Mitsui, Schott Pharma and DuPont.
Chemicals/Chemical API Manufacturing
* Carbogen Amcis Co-Investing $31.5 M for ADC Expansion
* Euroapi Appoints New Chief Commercial Officer
* PharmaLogic Appoints New CEO
* Antheia Raises $56 M for Commercial Strategy
Biologics Manufacturing
* WuXi Biologics Begins Construction on New Microbial Mfg Facility
* Resilience To Wind Down Some Mfg Operations
* Simtra, MilliporeSigma Partner for ADC Mfg
* Fujifilm Rebrands Companies as Part of New Strategy
* Made Scientific Expands Cell-Therapy Mfg
* Cellares, Mitsui Announce new Cell-Therapy Mfg Facility
Packaging
* SCHOTT Pharma Breaks Ground on New Packaging Mfg Facility
* DuPont Expands Sterile Packaging Ops
Chemicals/Chemical API Manufacturing
Carbogen Amcis Co-Investing $31.5 M for ADC Expansion
Carbogen Amcis, a Bubendorf, Switzerland-based CDMO of drug substances and drug products,, has announced a co-investment of more than CHF 25 million ($31.5 million) with a long-standing Japanese customer to expand manufacturing capabilities at its sites in Aarau and Neuland, Switzerland.
The investment will support the production of a drug linker for a commercial antibody-drug conjugate (ADC) Both facilities will see equipment and infrastructure enhancements, including:
- Aarau site: Installation of 850-litre reactors and 0.4-m² agitated filter dryers with supporting equipment. Completion is expected by the first quarter of 2027.
- Neuland site: installation of 850-litre reactors and 0.4-m² agitated filter dryers with auxiliary systems. Completion is anticipated by the third quarter of 2027.
Source: Carbogen Amcis
Euroapi Appoints New Chief Commercial Officer
Euroapi, a supplier and CMDO of active pharmaceutical ingredients (APIs) that was spun off from Sanofi in 2022, has appointed Frédéric Robert to the newly created position of Chief Commercial Officer overseeing API Solutions and CDMO activities.
He will join the company’s Executive Committee. This appointment comes as part of the company’s restructuring plan, dubbed Focus 27, which is aimed at improving the company’s financial performance. Euroapi has two main business activities. It is a supplier of APIs and has a CDMO business. Its restructuring plan involves four main elements: streamlining its API portfolio to more value-added products, increasing the revenue share of its CDMO business, consolidating its manufacturing footprint, and reducing headcount.
In his new role, Robert will be responsible for creating commercial and organizational synergies between the API Solutions and CDMO operation, expanding the group’s presence in its strategic markets and with its strategic clients, and optimizing its customer approach with integrated, high-value-added solutions.
Source: Euroapi
Antheia Raises $56 M for Commercial Strategy
Antheia, a pharmaceutical ingredient producer, has raised $56 million in Series C financing. The new financing will be used to expand commercialization of Antheia’s first product, thebaine, and to launch additional products from the company’s pipeline of 70+ biosynthetic pharmaceutical ingredients. Additionally, the funding will be used for its US manufacturing operations to meet domestic demand and to begin new programs in Singapore while expanding into the broader Asia region.
Source: Antheia
PharmaLogic Appoints New CEO
PharmaLogic Holdings, a CDMO specializing in radiopharmaceuticals, has appointed Etienne Montagut, currently serving as President, to the position of President and Chief Executive Officer, following the retirement of Steve Chilinski, formerly CEO, effective as of June 1, 2025. Chilinski assumes the role of Executive Chairman of the Board after serving as CEO for 13 years.
Montagut brings over 25 years of senior leadership experience in the pharmaceutical sector. Prior to joining PharmaLogic one year ago, he held executive positions at Lantheus, GE HealthCare, and Ipsen.
.Source: PharmaLogic
Biologics Manufacturing
Resilience To Wind Down Some Mfg Operations
National Resilience, a CDMO of biologics and advanced therapies, has announced that it plans to wind down operations at some of its sites due to recent expansions being outpaced by industry demand. The company made the announcement as part of a letter to customers.
“Most recently, we have determined that the best use of our expertise, resources, and talent is to focus on high-growth segments to advance cell-based medicines, primarily biologics, and aseptic drug product operations,” said William Marth, President & Chief Executive Officer, Resilience, in a June 2, 2025, statement. “It has also become clear that our capacity expansion has outpaced industry demand. As a result, we have been consolidating our operations to pursue a tailored business strategy with a streamlined footprint. To advance our transformation while continuing to serve our customers with excellence, it was determined that sites not being fully utilized needed to be wound down in a prompt and efficient manner through legal proceedings commenced by a leaseholder affiliate.”
The company says certain manufacturing operations, including its Cincinnati facility, remain fully operational and are not included in those proceedings. Existing institutional Investors provided $250 million in bridge financing to support these changes.
Source: National Resilience
WuXi Biologics Begins Construction of New Microbial Mfg Facility
WuXi Biologics, a CDMO of biologics, has begun construction of a new microbial manufacturing site for commercial production in the Wenjiang district of Chengdu, China.
Spanning an area of 95,000 square meters, the new site is dedicated to a drug-substance facility and a drug-product facility for commercial manufacturing to produce a wide array of modalities, such as peptides, antibody fragments, plasmid DNA, enzymes, cytokines, and virus-like particles (VLPs). Scheduled to complete GMP release for production by the end of 2026, the site will be equipped with a 15,000-L fermenter to enable annual production capacity of 80 to 110 drug-substance batches. In the long run, capacity will be able to expand to 60,000 L. The facility will house a dual-chamber lyophilization production line alongside a vial filling line, with overall drug-product manufacturing capacity exceeding 10 million vials annually.
Source: WuXi Biologics
Simtra, MilliporeSigma Partner for ADC Mfg
Simtra BioPharma Solutions, a CDMO specializing in sterile injectables, has formed a five-year strategic alliance with MilliporeSigma to provide manufacturing services for antibody drug conjugate (ADC) drug substances and drug-products. The partnership creates a turnkey offering for bio/pharmaceutical companies seeking ADC and bioconjugation, linker/payload manufacturing, drug product formulation development, and fill–finish capabilities.
Source: Simtra BioPharma Solutions
Fujifilm Corp. Rebrands Life Sciences Companies
Fujifilm Corporation’s Life Sciences Group companies, a portfolio of businesses offering products, services and solutions that span all stages of therapeutic development from discovery through to commercialization, have announced new names and identities as part of a strategic positioning effort.
Fujifilm Irvine Scientific, headquartered in Santa Ana, California, which provides discovery and research reagents, recombinant growth factors and proteins, specialty chemicals, assay materials, and cell-culture media, rebrands as Fujifilm Biosciences. The new brand name will take effect immediately (as reported on June 2, 2025), and the legal entity name change will be effective January 1, 2026. Fujifilm Diosynth Biotechnologies, a CDMO of biologics and advanced therapies, first acquired by the Fujifilm Group in 2011, rebrands to Fujifilm Biotechnologies. The company’s legal name will not change.
Source: Fujifilm Corporation
Made Scientific Expands Cell Therapy Mfg
Made Scientific, a CDMO of cell therapies, has announced an expansion of its facility in Princeton, New Jersey. The 12,000-square-foot expansion will add over 9,000 square feet of GMP manufacturing cleanroom space across two phases.
Phase 1 of the commercial expansion is set to initiate in the second quarter of 2025, and will be completed by the third quarter of 2026, with Phase 2 planned thereafter. Once complete, the site will enable throughput of up to 2,000 additional manufacturing batches per year.
Source: Made Scientific
Cellares, Mitsui Announce new Cell Therapy Mfg Facility
Cellares, a South San Francisco, California-based CDMO of cell therapies, in collaboration with Mitsui Fudosan, has announced the establishment of a commercial production site for CAR-T cell therapies in Kashiwa City, Tokyo. The facility, now under construction, is set to open in partnership with Mitsui Fudosan, will use Cellares’ technology platforms, the Cell Shuttle and Cell Q, to automate cell therapy manufacturing and quality control.
Source: Cellares
Packaging
SCHOTT Pharma Breaks Ground on New Packaging Mfg Facility
SCHOTT Pharma, a pharmaceutical packaging company, is investing more than EUR 100 million ($116 million) in its existing site in Lukácsháza, Hungary, to expand capacity for sterile ready-to-use (RTU) cartridges.
Following the opening of a new facility for pre-fillable glass syringes at the site in 2024, the company has now broken ground for another facility that will add further manufacturing capacity for high-value solutions. The move aligns with the company’s expansion strategy to increase its share of these high-margin products. RTU cartridges are used to store biologics, GLP-1 drugs, insulin, or hormone therapies to treat diabetes, obesity, or other immunological diseases. The new facility will bring over 100 additional jobs to the region.
Source: SCHOTT Pharma
DuPont Expands Sterile Packaging Ops
DuPont has expanded its sterile operations via an addition to its healthcare manufacturing facility in Heredia, Costa Rica, to enable the site to produce sterile packaging for the global medical device industry while also increasing the capacity of the site’s existing medical tubing operations. The Heredia operation has expanded by 16,000 square feet. The new space accommodates additional extrusion equipment and production lines to enable production of sterile packaging such as pouches, header bags and lids and increases DuPont’s extruded tubing production capacity.
Source: DuPont
